vs
Side-by-side financial comparison of BRUNSWICK CORP (BC) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
BRUNSWICK CORP is the larger business by last-quarter revenue ($1.4B vs $1.1B, roughly 1.2× PERRIGO Co plc). BRUNSWICK CORP runs the higher net margin — 1.5% vs -127.8%, a 129.3% gap on every dollar of revenue. On growth, BRUNSWICK CORP posted the faster year-over-year revenue change (17.3% vs -2.5%). PERRIGO Co plc produced more free cash flow last quarter ($148.6M vs $-116.8M). Over the past eight quarters, PERRIGO Co plc's revenue compounded faster (1.3% CAGR vs -2.3%).
Brunswick Corporation, formerly known as the Brunswick-Balke-Collender Company, is an American corporation that has been developing, manufacturing and marketing a wide variety of products since 1845. Brunswick has more than 13,000 employees in 24 countries. Brunswick owns a number of brands, including Mercury Marine. In 2024, Brunswick reported sales of US$5.2 billion. Brunswick's global headquarters is in the northern Chicago suburb of Mettawa, Illinois.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
BC vs PRGO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $1.1B |
| Net Profit | $21.0M | $-1.4B |
| Gross Margin | 24.9% | 32.6% |
| Operating Margin | 3.6% | -116.0% |
| Net Margin | 1.5% | -127.8% |
| Revenue YoY | 17.3% | -2.5% |
| Net Profit YoY | — | -3093.9% |
| EPS (diluted) | $0.32 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.4B | — | ||
| Q4 25 | $1.3B | $1.1B | ||
| Q3 25 | $1.4B | $1.0B | ||
| Q2 25 | $1.4B | $1.1B | ||
| Q1 25 | $1.2B | $1.0B | ||
| Q4 24 | $1.2B | $1.1B | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $1.4B | $1.1B |
| Q1 26 | $21.0M | — | ||
| Q4 25 | $18.7M | $-1.4B | ||
| Q3 25 | $-235.5M | $7.5M | ||
| Q2 25 | $59.3M | $-8.4M | ||
| Q1 25 | $20.2M | $-6.4M | ||
| Q4 24 | $-82.5M | $-44.4M | ||
| Q3 24 | $44.6M | $-21.0M | ||
| Q2 24 | $100.0M | $-108.4M |
| Q1 26 | 24.9% | — | ||
| Q4 25 | 23.1% | 32.6% | ||
| Q3 25 | 25.8% | 36.1% | ||
| Q2 25 | 25.5% | 34.4% | ||
| Q1 25 | 24.9% | 37.6% | ||
| Q4 24 | 21.9% | 33.9% | ||
| Q3 24 | 26.2% | 37.2% | ||
| Q2 24 | 27.1% | 37.0% |
| Q1 26 | 3.6% | — | ||
| Q4 25 | 3.1% | -116.0% | ||
| Q3 25 | -17.8% | 7.0% | ||
| Q2 25 | 7.1% | 4.3% | ||
| Q1 25 | 4.6% | 4.5% | ||
| Q4 24 | -4.8% | 10.0% | ||
| Q3 24 | 7.7% | 7.4% | ||
| Q2 24 | 11.0% | -2.5% |
| Q1 26 | 1.5% | — | ||
| Q4 25 | 1.4% | -127.8% | ||
| Q3 25 | -17.3% | 0.7% | ||
| Q2 25 | 4.1% | -0.8% | ||
| Q1 25 | 1.7% | -0.6% | ||
| Q4 24 | -7.1% | -3.9% | ||
| Q3 24 | 3.5% | -1.9% | ||
| Q2 24 | 6.9% | -10.2% |
| Q1 26 | $0.32 | — | ||
| Q4 25 | $0.32 | $-10.23 | ||
| Q3 25 | $-3.59 | $0.05 | ||
| Q2 25 | $0.89 | $-0.06 | ||
| Q1 25 | $0.30 | $-0.05 | ||
| Q4 24 | $-1.21 | $-0.32 | ||
| Q3 24 | $0.67 | $-0.15 | ||
| Q2 24 | $1.48 | $-0.79 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $277.8M | — |
| Total DebtLower is stronger | $490.2M | — |
| Stockholders' EquityBook value | $1.6B | $2.9B |
| Total Assets | $5.5B | $8.5B |
| Debt / EquityLower = less leverage | 0.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $277.8M | — | ||
| Q4 25 | $256.8M | — | ||
| Q3 25 | $297.7M | $432.1M | ||
| Q2 25 | $315.7M | $454.2M | ||
| Q1 25 | $286.7M | $409.9M | ||
| Q4 24 | $269.0M | $558.8M | ||
| Q3 24 | $284.1M | $1.5B | ||
| Q2 24 | $494.5M | $542.8M |
| Q1 26 | $490.2M | — | ||
| Q4 25 | $2.1B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $1.6B | — | ||
| Q4 25 | $1.6B | $2.9B | ||
| Q3 25 | $1.6B | $4.4B | ||
| Q2 25 | $1.9B | $4.5B | ||
| Q1 25 | $1.9B | $4.4B | ||
| Q4 24 | $1.9B | $4.3B | ||
| Q3 24 | $2.0B | $4.6B | ||
| Q2 24 | $2.0B | $4.5B |
| Q1 26 | $5.5B | — | ||
| Q4 25 | $5.3B | $8.5B | ||
| Q3 25 | $5.4B | $10.1B | ||
| Q2 25 | $5.8B | $10.1B | ||
| Q1 25 | $5.9B | $9.8B | ||
| Q4 24 | $5.7B | $9.6B | ||
| Q3 24 | $6.0B | $11.2B | ||
| Q2 24 | $6.4B | $10.4B |
| Q1 26 | 0.31× | — | ||
| Q4 25 | 1.30× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.25× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $175.4M |
| Free Cash FlowOCF − Capex | $-116.8M | $148.6M |
| FCF MarginFCF / Revenue | -8.5% | 13.4% |
| Capex IntensityCapex / Revenue | 4.2% | 2.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $344.6M | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $132.9M | $175.4M | ||
| Q3 25 | $140.4M | $51.7M | ||
| Q2 25 | $316.2M | $75.9M | ||
| Q1 25 | $-27.4M | $-64.5M | ||
| Q4 24 | $306.4M | $312.6M | ||
| Q3 24 | $67.4M | $42.2M | ||
| Q2 24 | $211.0M | $9.5M |
| Q1 26 | $-116.8M | — | ||
| Q4 25 | $83.6M | $148.6M | ||
| Q3 25 | $106.5M | $29.8M | ||
| Q2 25 | $271.3M | $56.7M | ||
| Q1 25 | $-65.1M | $-90.0M | ||
| Q4 24 | $276.1M | $274.9M | ||
| Q3 24 | $31.4M | $15.1M | ||
| Q2 24 | $163.9M | $-18.9M |
| Q1 26 | -8.5% | — | ||
| Q4 25 | 6.3% | 13.4% | ||
| Q3 25 | 7.8% | 2.9% | ||
| Q2 25 | 18.7% | 5.4% | ||
| Q1 25 | -5.3% | -8.6% | ||
| Q4 24 | 23.9% | 24.2% | ||
| Q3 24 | 2.5% | 1.4% | ||
| Q2 24 | 11.4% | -1.8% |
| Q1 26 | 4.2% | — | ||
| Q4 25 | 3.7% | 2.4% | ||
| Q3 25 | 2.5% | 2.1% | ||
| Q2 25 | 3.1% | 1.8% | ||
| Q1 25 | 3.1% | 2.4% | ||
| Q4 24 | 2.6% | 3.3% | ||
| Q3 24 | 2.8% | 2.5% | ||
| Q2 24 | 3.3% | 2.7% |
| Q1 26 | — | — | ||
| Q4 25 | 7.11× | — | ||
| Q3 25 | — | 6.89× | ||
| Q2 25 | 5.33× | — | ||
| Q1 25 | -1.36× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.51× | — | ||
| Q2 24 | 2.11× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BC
Segment breakdown not available.
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
